{"filings":[{"id":1316316,"accession_number":"0001193125-26-286969","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K/A","filed_at":"2026-06-29T13:06:19+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Myomo stockholders vote to increase authorized shares to 100M and expand stock plan by 1.83M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved charter amendment increasing authorized common shares to 100,000,000.","Stockholders approved Amendment No. 3 to 2018 Stock Plan, adding 1,833,000 shares for issuance.","Elected Paul R. Gudonis and Thomas F. Kirk as Class III directors for terms expiring in 2029.","Ratified CBIZ CPAs P.C. as independent registered public accounting firm for FY 2026.","Advisory votes passed on executive compensation and a stockholder proposal on director classification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1303924,"accession_number":"0001193125-26-285450","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2026-06-26T20:05:28+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Myomo shareholders approve 100M authorized shares and 1.833M share plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Paul R. Gudonis and Thomas F. Kirk as Class III directors to three-year terms expiring 2029.","Authorized common stock increased to 100M shares; 20.7M for, 3.1M against.","Stock plan increased by 1.833M shares via Amendment No. 3; 10.8M for, 3.7M against.","Advisory say-on-pay vote passed with 13.7M for, 0.7M against.","Non-binding stockholder proposal on director classification passed with 13.2M for, 2.0M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68206,"accession_number":"0001193125-26-221624","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2026-05-13T20:10:16+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Myomo appoints Joseph Manko Jr., founder of Horton Capital, as director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph M. Manko Jr. appointed as Class I director effective May 9, 2026, through 2027 annual meeting.","Manko is Senior Principal of Horton Capital Management, a significant Myomo shareholder.","Over 25 years in investment banking, private equity, and corporate strategy.","Also serves on boards of Safeguard Scientifics and KORU Medical Systems.","Will receive standard non-employee director compensation ($60k cash + $85k RSUs)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92453,"accession_number":"0001193125-26-211928","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q1 revenue $10.1M (+3% YoY); net loss narrows to $3.0M; guides Q2 $10.3M-$10.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $10.1M (+3% YoY), net loss $3.0M ($0.07/sh) vs $3.5M loss ($0.08/sh) in Q1 2025.","Gross margin expanded to 68.2% (up 100 bps); operating expenses down 1% YoY to $10.1M.","Orders received 239 (+12% YoY); backlog 226 (+14% vs Dec 2025); pipeline adds up 7% sequentially.","Recurring patient source revenue reached 49% of total, up from 25% a year ago.","Q2 2026 revenue guidance $10.3M-$10.8M; FY 2026 revenue reiterated at $43M-$46M."],"consensus_eps_estimate":-0.1151,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":10113288.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92452,"accession_number":"0001193125-26-159060","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Myomo appoints William J. Febbo to Board, effective April 14, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Febbo, 57, is CEO of Performance Health Systems and former CEO of OptimizeRx (OPRX), where he grew revenue from $5M to $92M.","He received 45,000 RSUs vesting on first anniversary, plus $60K annual cash retainer and $85K annual RSU retainer.","Appointment expands Board to six directors; Febbo serves as Class II director until 2028 annual meeting.","Chairman Paul Gudonis cited Febbo's expertise in scaling direct-to-patient healthcare and capital markets credibility.","Febbo co-founded Merriman Holdings and Digital Capital Network; also MIT linQ faculty and Harvard Business School mentor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103301,"accession_number":"0001193125-26-098504","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q4 revenue falls 6% to $11.4M; net loss widens to $3.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $11.4M (-6% YoY); full year $40.9M (+26% YoY).","Q4 net loss $3.8M ($0.09/sh) vs loss $0.3M in Q4 2024; full year loss $15.6M.","Record 241 authorizations/orders in Q4; 42% of revenue from recurring sources (vs 26% a year ago).","Introduces 2026 revenue guidance $43M-$46M; Q1 2026 guidance $9.0M-$9.5M.","Cash $18.4M at Dec 31, 2025; gross margin 68.6% in Q4 vs 71.4% prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119553,"accession_number":"0001193125-25-320896","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Myomo CEO & CFO take 10% salary cut in 2026, receiving RSUs at 115% of foregone amount","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Paul Gudonis voluntarily reduces 2026 base salary 10% ($40,000) for RSUs worth $46,000 (115% of foregone).","CFO David Henry voluntarily reduces 2026 base salary 10% ($30,000) for RSUs worth $34,500 (115% of foregone).","RSUs granted quarterly from Jan 12, 2026, vesting after three months; company may cancel program before Jan 12."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119552,"accession_number":"0001193125-25-274238","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["1.01","2.02","2.03","3.02","9.01"],"status":"ready","headline":"Myomo Q3 revenue $10.1M (+10% YoY); net loss $0.09/shr; FY guidance $40-42M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $10.1M, up 10% YoY; 186 units sold (+16%), ASP ~$54,200 (-5%).","Gross margin 63.8% vs 75.4% YoY due to higher costs, lower ASP, and unfavorable overhead absorption.","Net loss $3.7M ($0.09/shr) vs $1.0M loss ($0.03/shr) a year ago; operating loss $3.5M.","New $17.5M Avenue Capital loan; $12.5M funded, pro forma cash $20.1M after debt repayment and fees.","Reiterated FY2025 revenue guidance $40-42M; Q3 authorizations/orders 229 (best quarter of year)."],"consensus_eps_estimate":-0.1091,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":29574746.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136120,"accession_number":"0000950170-25-106562","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q2 revenue $9.7M (+28%) but operating loss widens; cuts FY2025 guidance to $40-42M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $9.7M (+28% YoY), revenue units 178 (+13%), ASP ~$54,200 (+14%).","Orders/authorizations 207 (-3%), backlog 230 units (-18%), pipeline adds 816 (+49%).","Operating loss $4.6M vs $1.1M; net loss $0.11/share vs $0.03; gross margin 62.7% vs 70.8%.","Cash $15.5M after $4M borrowings; ops used $8.9M cash; workforce cut ~8%, aiming to save $2M annually.","FY2025 revenue guidance cut to $40-42M from $50-53M (23-29% YoY growth); Q3 guided $9.5-10.0M."],"consensus_eps_estimate":-0.1071,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":19484048.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153175,"accession_number":"0000950170-25-087709","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Myomo sets 2028 revenue target of $100M, gross margin 70-72% at Investor Day","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aspirational goal of $100M annual revenue by 2028, including $15M international and $20M O&P channel revenue.","Manufacturing capacity to reach 250 MyoPros/month with existing plus new space available in July 2025.","Cost-reduction projects targeting ~200 bps gross margin improvement quarterly by end of 2026.","Targets: gross margin 70-72%, EBITDA margin 15-20%, cash flow breakeven at $17-18M quarterly revenue.","Private payer contracts cover 27M+ lives; lead generation recovered from early Q1 2025 challenges."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153174,"accession_number":"0000950170-25-086306","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Myomo stockholders elect Heather Getz as Class II director, ratify CBIZ as auditor for FY2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Heather Getz elected as Class II director for three-year term expiring at 2028 annual meeting; 10,294,384 for, 1,888,001 withheld, 12,131,966 broker non-votes.","Ratification of CBIZ CPAs P.C. as independent auditor for fiscal year ending Dec 31, 2025 passed: 23,797,191 for, 392,407 against, 124,753 abstain, no broker non-votes.","Annual Meeting held June 11, 2025; record date Apr 14, 2025 with 35,978,651 shares outstanding (including unvoted broker shares).","No other matters were submitted or voted on at the Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153173,"accession_number":"0000950170-25-065657","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q1 revenue $9.8M (+162%); record 700 pipeline adds; guides Q2 $9.0-9.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $9.8M (+162% YoY) on 182 units (+100%); gross margin 67.2% (up 600 bps).","Net loss $3.5M ($0.08/share) vs $3.8M loss last year; adj. EBITDA $(2.8)M.","Record 700 patients added to pipeline (+42% YoY); backlog 249 units (-9%).","Q2 2025 revenue guidance $9.0-9.5M; FY2025 reaffirmed at $50-53M.","Medicare Part B patients 59% of Q1 revenue; 45% of revenue from in-quarter authorizations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":9831814.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153172,"accession_number":"0000950170-25-052686","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["4.01","5.02","7.01","9.01"],"status":"ready","headline":"Myomo names CBIZ as new auditor; two directors exit board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as auditor April 8; CBIZ CPAs engaged after acquiring Marcum's attest business.","No disagreements with Marcum; but a material weakness in IT general controls was reported in the 2024 10-K.","Director Amy Knapp (served since 2016) not standing for reelection at June 2025 annual meeting; no disagreement.","Director Yitzchak Jacobovitz (since 2023) not standing for reelection; will transition to board observer role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171950,"accession_number":"0000950170-25-036280","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q4 revenue $12.1M record, first positive op. cash flow; guides FY2025 $50-53M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $12.1M (+154% YoY); 220 units shipped (+106%); ASP ~$54,900 (+23%).","First positive quarterly cash flow from operations at $3.4M; free cash flow $2.5M.","Record 233 MyoPro authorizations/orders (+27%); backlog 272 units (+18%).","Net loss narrowed to $0.3M ($0.01/sh) from $2.5M ($0.07/sh); Adjusted EBITDA $0.2M (first positive).","FY2025 revenue guidance $50-53M (+54-63% YoY); Q1 expected $9.0-9.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171949,"accession_number":"0000950170-25-023403","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["1.01","2.04","2.03","9.01"],"status":"ready","headline":"Myomo enters $3M term loan with SVB; revises revolver Medicare concentration limit","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $3M term loan available until Feb 28, 2026; repayable in 36 monthly installments from Mar 1, 2026, maturing Feb 1, 2029.","Interest on term loan at greater of 5.0% or prime minus 1.0%; prepayment fee 1%-3% based on prepayment year.","Revolving line Medicare receivables concentration limit raised to 50% (from prior); German subsidiary deposit limit increased to $1.5M.","Existing $4M revolver (expandable to $5.5M) retains July 11, 2026 maturity; 8.5% floor or prime+0.5% interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188951,"accession_number":"0001193125-24-271571","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Myomo prices $15M public offering of 3M shares at $5.00; underwriter option exercised in full","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3,000,000 shares priced at $5.00 each; gross proceeds of $15.0M expected before expenses.","Net proceeds estimated at ~$15.8M after underwriting discounts and offering expenses.","Underwriter's 30-day option for 450,000 additional shares exercised in full.","Proceeds to fund advertising, headcount, O&P channel, product development, working capital.","Offering expected to close December 6, 2024; Craig-Hallum sole managing underwriter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188950,"accession_number":"0000950170-24-122298","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q3 revenue record $9.2M (+81% YoY); FY guidance raised to $30-31M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q3 product revenue $9.2M, +83% YoY; net loss $1.0M ($0.03/sh) vs $2.0M loss year ago.","Gross margin 75.4%, +670 bps; backlog record 316 units (+71%); 225 MyoPro orders (+44%).","Raised FY2024 revenue guidance to $30-31M from prior $28-30M; expects Q4 rev $9.5-10.5M.","Cash $7.0M; expects approaching operating cash flow breakeven in Q4.","Cost per pipeline add $1,618, down 25%; 1,263 patients in pipeline (+21%)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":20482742.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205423,"accession_number":"0000950170-24-096326","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Myomo signs 88-month lease for 36,208 sq ft in Burlington, MA for HQ and manufacturing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease for approx. 36,208 rentable sq ft at 45 Blue Sky Drive; monthly rent starts at $96,250 and escalates over 8-year term.","Phase 1 occupancy of 28,708 sq ft expected by Nov 15, 2024; Phase 2 (7,500 sq ft) by June 1, 2025.","Tenant improvement allowance of $700,000; $375,000 letter of credit cash-collateralized.","Fixed monthly rent ranges from $96,250 (first year) to $147,849 (year 8); term approx. 88 months.","One five-year extension option subject to net income and continuous occupancy conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205422,"accession_number":"0000950170-24-091801","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q2 2024 revenue $7.5M (+77% product revenue); record 213 MyoPro orders","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $7.5M (+77% YoY); total revenue $7.5M (+26% YoY) reflecting prior-year license fee.","Record 213 MyoPro authorizations/orders (+70% YoY); backlog 282 units (+58% YoY).","1,179 patients in pipeline (+22% YoY); 550 new candidates added in Q2 (+35% YoY).","Gross margin 70.8% (product GM up 1,030 bps to 70.8%); net loss $1.1M ($0.03 EPS).","Q3 revenue guidance $8.0-8.5M; FY2024 revenue target $28-30M; targeting Q4 operating cash flow breakeven."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":11275156.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205421,"accession_number":"0001193125-24-179060","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Myomo enters $4M revolving credit facility with Silicon Valley Bank","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolver up to $4M (expandable to $5.5M); interest rate greater of 8.50% or prime + 0.50%.","Facility secured by all assets except intellectual property; matures July 2026.","Fees include $20K commitment fee, 0.50% anniversary fee, 0.50% unused line fee, and 1% termination fee.","Proceeds for working capital and general business purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205420,"accession_number":"0000950170-24-081953","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo expects record Q2 revenue $7.2M-$7.4M, up 92-97% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 revenue $7.2M-$7.4M, 92-97% sequential increase, highest ever.","Revenue units 155-160, up 70-76% vs Q1's 91 units.","Record pipeline additions ~550, record authorizations/orders ~210.","CMS payments faster than anticipated; now booking Medicare Part B revenue on delivery from July 1.","Exited Q2 with nearly 150 employees; hiring on track."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":11275156.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222333,"accession_number":"0001193125-24-157320","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Myomo shareholders elect Crowley and Morris as Class I directors, ratify Marcum as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Thomas A. Crowley received 9,246,482 votes for, 1,049,041 withheld, and 11,747,021 broker non-votes.","Milton M. Morris received 10,225,559 votes for, 71,194 withheld, and 11,745,791 broker non-votes.","Ratification of Marcum LLP as independent auditor: 21,615,373 for, 425,595 against, 1,576 abstain.","No other matters were voted on at the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222332,"accession_number":"0000950170-24-055687","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q1 revenue $3.8M (+9% YoY); backlog record 275 units; net loss $3.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.8M (+9% YoY); product revenue $3.75M; revenue units 91 (+14%).","Net loss $3.8M ($0.10/share) vs $2.6M loss a year ago; operating loss $3.9M.","Gross margin 61.2% (down 580bps) on lower ASP, higher warranty reserve and material costs.","Record backlog 275 units (+56%), includes 83 Medicare Part B; orders/authorizations 180 (+48%).","Q2 revenue guidance >$5M; FY2024 guidance $28M-$30M; expects operating cash flow breakeven by Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":3754389.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222331,"accession_number":"0000950170-24-053228","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Myomo receives first lump sum Medicare reimbursements for MyoPro under new CMS fees","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS through DME MACs remitted lump sum reimbursements for MyoPros to Medicare Part B beneficiaries.","Payments based on published fees for HCPCS codes L8701 and L8702 effective April 1, 2024.","All four regional DME MACs have remitted payments; first claim paid for a MyoPro Center of Excellence provider.","CEO states greater clarity of reimbursement for channel partners and health professionals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241858,"accession_number":"0000950170-24-038054","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Myomo appoints Heather Getz to board as director and audit committee chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 6 to 7 members; Ms. Getz appointed as Class II director effective March 26, 2024.","Ms. Getz serves until 2025 annual meeting; also chairs audit committee and is independent.","Compensation: $55,000 annual cash retainer (incl. $5,000 committee chair fee) plus $30,000 in RSUs vesting quarterly.","Ms. Getz is EVP and CFO/COO of Butterfly Network (BFLY), with over 25 years of finance and healthcare leadership experience.","She is a CPA and holds an MBA and BS in Accountancy from Villanova University."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241857,"accession_number":"0000950170-24-027949","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q4 revenue $4.8M (+18% YoY), backlog record 230 units, guides FY2024 rev $28M-$30M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue $4.756M (+18% YoY); recognized 107 MyoPro units (+6%).","Net loss $2.5M ($0.07/shr) vs $2.2M ($0.29/shr) in Q4 2022; adjusted EBITDA -$2.1M.","Record backlog 230 units (+40% YoY), including 44 Medicare Part B patients receiving rental payments or qualified.","Q1 2024 revenue guidance $4.1M-$4.3M; full year 2024 revenue target $28M-$30M with operating cash flow breakeven targeted by Q4.","CMS finalized HCPCS fees for MyoPro codes L8701 ($33,480.90) and L8702 ($65,871.74) effective April 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241856,"accession_number":"0000950170-24-023543","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CMS finalizes Medicare fee schedule for Myomo's MyoPro at $33,481-$65,872 per device","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS final fee schedule rates: L8701 (Motion W) $33,480.90, L8702 (Motion G) $65,871.74, effective April 1, 2024.","MyoPro classified as brace benefit category on Jan 1, 2024, enabling lump-sum reimbursement.","CEO Paul Gudonis calls it 'important milestone' for Medicare Part B beneficiaries and the company.","Process started in 2018 with HCPCS coding; now final rates enable billing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241855,"accession_number":"0000950170-24-018877","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Myomo amends CFO Henry's salary to $260K; CMO Kovelman gets new severance terms","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO David Henry: base salary raised from $221,500 to $260,000; annual incentive cap reduced from 75% to 55% of base.","CFO Henry: full acceleration of time-based and performance-based stock awards upon change in control with measurement date accelerated.","CMO Harry Kovelman: severance of 50% salary plus pro-rata bonus upon termination without cause, plus 6-month COBRA and 6-month vesting acceleration.","Kovelman: termination within 12 months after change in control triggers 9-month payout and immediate full vesting of all stock awards.","Both amendments effective February 21, 2024; Kovelman's agreement restates prior change-in-control and severance agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241854,"accession_number":"0001193125-24-009264","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"Myomo reports prelim Q4 revenue $4.6-$4.8M (+14-19% YoY), raises $6M in registered direct offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2023 revenue expected $4.6-$4.8M, up 14-19% YoY; cash $8.7M at Dec 31, 2023.","Backlog of ~230 patients as of Dec 31, 2023, up ~40% YoY; CMS classified MyoPro as a brace, reimbursed lump sum.","Raised $6M gross via registered direct offering of 1.58M shares/pre-funded warrants at $3.80, priced at market.","Proceeds to scale up for Medicare Part B, hire ~50 people; expects cash flow breakeven by Q4 2024.","CEO targets $100M annual revenue within five years; offering includes insiders and institutional investors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":19241158.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259298,"accession_number":"0000950170-23-071510","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2023-12-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Myomo renews CEO Paul Gudonis employment agreement; $350K base salary, term through Dec 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary of $350,000 with annual bonus opportunity up to 75% of base, effective Jan 1, 2024.","Three-year at-will term expiring December 31, 2026, automatically continuing unless modified in writing.","Termination without cause triggers 12 months base salary, bonus, COBRA payments, and accelerated vesting of stock awards for 12 months.","If terminated without cause within 12 months after a change in control, all stock options and time-based awards fully vest immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259297,"accession_number":"0000950170-23-060269","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q3 record product revenue $5.0M, up 27% YoY; net loss narrows to $2.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $5.1M (+28% YoY); product revenue $5.0M (+27%) on 119 units (+37%).","Net loss $2.0M ($0.06/share) vs $2.8M loss ($0.40/share) in Q3 2022; adjusted EBITDA ($1.7M).","Received 156 MyoPro orders/authorizations (+20%); pipeline hits 1,046 candidates (+28%).","CMS reclassifies MyoPro as brace effective Jan 1, 2024; proposed fee rates $31,745 and $62,457.","First Medicare Part B rental payments received from all four DME MACs; six claims filed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":14484775.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259296,"accession_number":"0000950170-23-059039","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CMS proposes Medicare reimbursement rates for MyoPro: $31,745 for L8701, $62,457 for L8702","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS proposed fee schedule rates: L8701 (Motion W) at $31,745.42 and L8702 (Motion G) at $62,457.28.","CMS final rule effective Jan 1, 2024 classifies MyoPro as a brace for lump-sum reimbursement.","Public meeting to discuss proposed rates scheduled for November 29, 2023.","Company cautions that rates are proposed and not yet final; no assurance of finalization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259295,"accession_number":"0000950170-23-058168","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CMS classifies MyoPro as Medicare Part B brace, lump-sum reimbursement from Jan 1, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS final rule published Nov 1, effective Jan 1, 2024: MyoPro classified as a brace, paid lump sum.","Myomo received rental payments for five Medicare Part B patients covering all four CMS billing regions.","National fee not yet set; claims paid at regional DME MAC rates until determination at CMS public meeting.","CEO says reclassification supports health equity and aligns Medicare payment with other insurers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276562,"accession_number":"0001193125-23-222703","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2023-08-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Myomo raises $4.4M in registered public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering consists of 5,413,334 shares of common stock and 1,920,000 pre-funded warrants at $0.60 per share/$0.5999 per warrant.","Gross proceeds expected to be $4.4 million; net proceeds for general corporate purposes, including working capital, R&D, and sales.","Placement agent A.G.P. receives 6% cash fee plus $10k non-accountable expense and up to $50k accountable legal fees.","90-day lock-up on new equity issuance; 12-month prohibition on variable rate transactions.","Closing expected August 29, 2023; investors include 5% stockholder AIGH Capital Management and certain officers/employees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276561,"accession_number":"0000950170-23-044373","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2023-08-24T23:59:59+00:00","items":["1.02","8.01","9.01"],"status":"ready","headline":"Myomo receives first Medicare Part B payments for MyoPro; terminates Keystone stock agreement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received payment on two MyoPro claims under Medicare Part B capped rental program (13-month payout).","CMS proposed rule would reclassify MyoPro to brace benefit category with lump-sum reimbursement; public comments due Aug 29, 2023.","Additional MyoPro claims are currently under review by DME MACs.","Terminated $5M common stock purchase agreement with Keystone Capital Partners by mutual consent; no penalties incurred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276560,"accession_number":"0000950170-23-040584","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q2 revenue up 62% to $6.0M; net loss narrows to $1.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $4.2M (+15% YoY); revenue units 97 (+21%). Total revenue includes $1.7M JV license fee.","Gross margin 71.8% vs 65.3%; net loss $1.0M ($0.04/sh) vs $2.9M loss ($0.42/sh) YoY.","Patient pipeline 969 candidates (+27%); 408 new candidates added in Q2 (+57%).","CMS proposed rule may expand brace definition to include MyoPro; Medicare Part B reimbursement anticipated in 6-12 months.","Outlook: modest Q3 YoY growth; full-year product revenue growth target of 20-30% dependent on authorizations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":9405252.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294321,"accession_number":"0000950170-23-027137","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Myomo stockholders re-elect 2 directors, approve 1.1M share plan increase, say-on-pay every 3 years","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paul R. Gudonis and Thomas F. Kirk re-elected as Class III directors through 2026 annual meeting.","Advisory say-on-pay approved; next vote set for 2026 annual meeting.","Marcum LLP ratified as independent auditor for fiscal year 2023.","Amendment No. 2 to 2018 Stock Plan approved, increasing authorized shares by 1,100,000.","All proposals passed; no broker non-votes on ratification or stock plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294320,"accession_number":"0000950170-23-020555","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q1 product rev up 20% to $3.4M; record 438 pipeline patients added","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $3.4M, +20% YoY; total revenue $3.4M (-11% due to prior-year license fee).","Record 438 new pipeline patients from previous payers (+54% YoY); total pipeline 855 (+28%).","Cost per pipeline add $1,579 (down 53% YoY, 50% sequentially).","Net loss $2.6M ($0.11 per share) vs $2.8M ($0.43) in Q1 2022.","Guides 20-30% product revenue growth for 2023; cash $11M after April license fee."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":3446708.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294319,"accession_number":"0000950170-23-012238","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2023-04-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Myomo receives $1.7M final license fee from China JV, enabling MyoPro manufacturing and sales in China","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received final $1.7M of initial license fee from Jiangxi Myomo JV; total upfront fee now $2.7M.","Enables start of technology transfer to JV for MyoPro manufacture and sale in China, Hong Kong, Taiwan, Macau.","JV committed to purchase at least $10.75M in MyoPro Control System Units over 10 years, subject to regulatory approvals.","Myomo owns 19.9% of JV; majority partner is Anhui Ryzur Medical Equipment Manufacturing.","Payment will be recognized as license revenue in Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314927,"accession_number":"0000950170-23-007459","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q4 revenue flat at $4.0M; net loss improves to $0.29/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue $4.0M, flat YoY and up 2% sequentially; 101 units (down 6% YoY).","Net loss attributable to common stockholders $2.2M ($0.29/share) vs $3.4M ($0.52) prior year.","Gross margin 65.0% (down from 77.4% YoY) due to inflationary costs; operating expenses down 17%.","Patient pipeline added 387 new candidates (+75% YoY); cost per pipeline add down 45% to $2,665.","Jan 2023 workforce cut 12% to save ~$2.0M; guided Q1 product revenue +15-20% YoY, FY +20-30%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314926,"accession_number":"0000950170-23-001376","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2023-01-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Myomo appoints Yitzchak Jacobovitz to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from five to six members; Jacobovitz appointed Class II director effective Jan 27, 2023.","Jacobovitz is partner and lead healthcare analyst at AIGH Capital Management, lead investor in recent equity offering.","No committee assignments yet; compensation to be determined.","Appointment follows Securities Purchase Agreement dated Jan 11, 2023 with AIGH and other investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314925,"accession_number":"0000950170-23-000773","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2023-01-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Myomo raises $6.5M in registered offering of 13.17M shares and pre-funded warrants at $0.325","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $6.5M from sale of 13,169,074 shares at $0.325 and pre-funded warrants for 6,830,926 shares at $0.3249.","Closing expected Jan 17, 2023; net proceeds for working capital and general corporate purposes.","A.G.P./Alliance Global Partners serves as placement agent with 7% cash fee.","AIGH Capital Management may appoint a Class II director if it holds at least 4M shares.","90-day lock-up on equity issuances and 12-month restriction on variable rate transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314924,"accession_number":"0000950170-23-000624","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Myomo reduces workforce by 12% to cut annual expenses by $2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of 12%, primarily affecting call center and administrative staff.","Expected annual savings of over $2 million from this and other cost reduction actions.","Company aims to improve operating efficiency in direct billing channel and extend cash runway.","CEO cites need to improve operating leverage while pursuing Medicare Part B coverage for MyoPro."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333291,"accession_number":"0000950170-22-026154","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2022-12-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Myomo fails to convene special meeting to approve Keystone stock issuance; withdraws proposals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting on Dec 7, 2022 lacked quorum; only majority of proxies received were in favor.","Proposal 1: Issue common stock to Keystone Capital Partners under August 2 purchase agreement in excess of Exchange Cap.","Proposal 2: Adjourn meeting to solicit more proxies; both proposals withdrawn.","Company will pursue other means to raise additional capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333290,"accession_number":"0000950170-22-024507","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo reports Q3 product revenue $4.0M, up 8% sequentially; record backlog of 184 units","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $4.0M, down 9% YoY but up 8% sequentially; revenue units 87, down 15% YoY.","Backlog hit record 184 units, up 13% sequentially; 130 authorizations/orders received, up 27% sequentially.","Net loss $2.8M ($0.40 per share) vs $2.1M loss ($0.36) a year ago; gross margin 66.5% vs 74.7% YoY.","Cash $7.4M at Sept 30; management expects modest sequential product revenue growth in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":11513702.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350778,"accession_number":"0000950170-22-018906","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2022-09-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CMS defers Myomo's request to reclassify MyoPro as brace; decision expected Q1 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS declined to rule on Myomo's request to reclassify MyoPro from rental DME to lump-sum brace.","CMS states it needs more time to evaluate benefit scope for arm and leg braces generally.","Final determination now expected during the Q1 2023 coding cycle.","Myomo had requested the reclassification to improve reimbursement terms (lump sum vs rental)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350777,"accession_number":"0000950170-22-014246","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q2 revenue up 18% to $3.7M; record pipeline adds 52% YoY; net loss widens to $0.42/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.7M (+18% YoY, +28% seq); product units 80, flat YoY; ASP up via direct billing (83% of revenue).","Record 420 new patient pipeline adds (+52% YoY); total pipeline 1,049; cost per addition halved from Q4 2021 to ~$2,470.","Gross margin 65.5%, down 550 bps YoY; net loss $2.9M ($0.42/shr) vs $2.6M ($0.46/shr) in Q2 2021.","Backlog 163 units (+2% YoY); operating loss $2.9M vs $2.6M; cash $10.2M; entered ELOC with Keystone Capital.","License payment from China JV delayed; expects sequential Q3 growth but lower YoY revenue; pipeline supports 12-mo outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":7545501.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350776,"accession_number":"0001193125-22-210150","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Myomo enters $5M common stock purchase agreement with Keystone Capital Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $5M of common stock may be sold at Myomo's discretion; 50,000 commitment shares issued.","Purchase price based on market price at time of sale; no upper limit and no obligation for Myomo to sell.","Issuance capped at 19.99% of outstanding shares (1,399,348 shares) unless stockholder approval or price exceeds book/market value.","Proceeds to be used for working capital and general corporate purposes; Keystone prohibited from short sales.","Agreement terminates upon $5M aggregate purchases, Registration Statement expiry, or delisting among others."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350775,"accession_number":"0000950170-22-012519","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2022-07-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Myomo pre-announces Q2 revenue $3.4-3.6M, up 10-16% YoY; record pipeline adds","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 2022 revenue $3.4–$3.6M, up 10–16% vs Q2 2021; all product revenue.","Added >400 prospective MyoPro patients in Q2, a quarterly record; cost per pipeline add decreased.","Second JV license fee payment from China partner delayed due to COVID-19 banking/government backlog.","Participated in CMS public hearing for Benefit Category Determination to reclassify MyoPro as custom-fabricated brace.","Full Q2 results and conference call scheduled for August 3, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":7545501.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367978,"accession_number":"0001193125-22-171934","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Myomo shareholders elect Amy Knapp director and ratify Marcum as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amy Knapp elected as Class II director with 2,458,836 for, 352,291 withheld.","Ratification of Marcum US LLP as auditor for FY2022 received 4,926,336 for, 79,730 against, 49,769 abstain.","Broker non-votes: 2,244,717 on director election; none on auditor ratification.","Meeting held June 8, 2022; 6,880,337 shares outstanding and entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-06-10T23:59:59+00:00|367978"}